Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1

H. E. Heslop; E. Benaim; M. K. Brenner; R. A. Krance; R. J. Rochester; L. M. Stricklin; R. Billing

doi:10.1016/S0140-6736(95)91621-0

Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1

H. E. Heslop, E. Benaim, M. K. Brenner, R. A. Krance, R. J. Rochester, L. M. Stricklin, R. Billing

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.

Original language	English (US)
Pages (from-to)	805-806
Number of pages	2
Journal	The Lancet
Volume	346
Issue number	8978
DOIs	https://doi.org/10.1016/S0140-6736(95)91621-0
State	Published - Sep 23 1995

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(95)91621-0

Cite this

@article{d909eaf33a4e47e2af3076758e8ad16d,

title = "Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1",

abstract = "Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.",

author = "Heslop, {H. E.} and E. Benaim and Brenner, {M. K.} and Krance, {R. A.} and Rochester, {R. J.} and Stricklin, {L. M.} and R. Billing",

note = "Funding Information: depletion with an antibody that destroys cells without regard to their activation stated This selectivity would be expected to preserve the anti-infective and antileukaemic properties of the donor graft, provided these desirable cells are not activated by the onset of GVHD. Third, the antibody is well tolerated in therapeutic doses for long periods. This study was supported in part by NIH grants CA 20180, CA 21745 (CORE) and by the American Lebanese Syrian Associated Charities (ALSAC).",

year = "1995",

month = sep,

day = "23",

doi = "10.1016/S0140-6736(95)91621-0",

language = "English (US)",

volume = "346",

pages = "805--806",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8978",

}

TY - JOUR

T1 - Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1

AU - Heslop, H. E.

AU - Benaim, E.

AU - Brenner, M. K.

AU - Krance, R. A.

AU - Rochester, R. J.

AU - Stricklin, L. M.

AU - Billing, R.

N1 - Funding Information: depletion with an antibody that destroys cells without regard to their activation stated This selectivity would be expected to preserve the anti-infective and antileukaemic properties of the donor graft, provided these desirable cells are not activated by the onset of GVHD. Third, the antibody is well tolerated in therapeutic doses for long periods. This study was supported in part by NIH grants CA 20180, CA 21745 (CORE) and by the American Lebanese Syrian Associated Charities (ALSAC).

PY - 1995/9/23

Y1 - 1995/9/23

N2 - Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.

AB - Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0029163618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029163618&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(95)91621-0

DO - 10.1016/S0140-6736(95)91621-0

M3 - Article

C2 - 7674747

AN - SCOPUS:0029163618

VL - 346

SP - 805

EP - 806

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8978

ER -

Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this